Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: A survey among Italian oncologists

Background: Increasing age of first pregnancy among Italian women with premenopausal breast cancer makes adjuvant hormonal therapy a hot topic, justifying a survey on the therapeutic approach of Italian oncologists. Materials & methods: From April to July 2012, an 11-item electronic questionnaire was submitted to Italian oncologists and 611 out of 974 invited filled questionnaires were collected from all over Italy. Results: In total, 97.7% of patients aged <40 years needing only hormonal therapy would receive both tamoxifen and luteinizing hormone-releasing hormone agonists (LHRHa); 2.3% tamoxifen or LHRHa alone. For the majority of oncologists LHRHa was also the preferred choice to preserving fertility. Conclusion: Results are rather consistent with major guidelines but with a greater use of LHRHa and aromatase inhibitor.

Data di pubblicazione: 2015
Titolo: Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: A survey among Italian oncologists
Autori: Barni, Sandro; Collovà, Elena; Frassoldati, Antonio; Amoroso, Domenico
Rivista: FUTURE ONCOLOGY
Parole Chiave: adjuvant hormone-therapy; premenopausal breast cancer; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Attitude of Health Personnel; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gonadotropin-Releasing Hormone; Humans; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pregnancy Tests; Premenopause; Surveys and Questionnaires; Tamoxifen; Fertility Preservation; Medical Oncology; Oncology; Cancer Research
Abstract in inglese: Background: Increasing age of first pregnancy among Italian women with premenopausal breast cancer makes adjuvant hormonal therapy a hot topic, justifying a survey on the therapeutic approach of Italian oncologists. Materials & methods: From April to July 2012, an 11-item electronic questionnaire was submitted to Italian oncologists and 611 out of 974 invited filled questionnaires were collected from all over Italy. Results: In total, 97.7% of patients aged <40 years needing only hormonal therapy would receive both tamoxifen and luteinizing hormone-releasing hormone agonists (LHRHa); 2.3% tamoxifen or LHRHa alone. For the majority of oncologists LHRHa was also the preferred choice to preserving fertility. Conclusion: Results are rather consistent with major guidelines but with a greater use of LHRHa and aromatase inhibitor.
Digital Object Identifier (DOI): 10.2217/fon.14.289
Handle: http://hdl.handle.net/11392/2377794
Appare nelle tipologie:03.1 Articolo su rivista

File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2022